We are grateful to our independent panel of experts who bring specialized knowledge and experience in innovation, healthcare and advocacy to our awards process.
Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support tracking cancer care, drug development, personalized medicine and scientific discovery. Joining Flatiron was the obvious next step.
Dr. Abernethy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine.
With over 400 publications, Amy is an internationally recognized expert in health services research, comparative effectiveness research, patient reported outcomes, clinical informatics and patient-centered care. She is an appointee to the Institute of Medicine’s National Cancer Policy Forum, on the Executive Board for the Personalized Medicine Coalition, and Past President of the American Academy of Hospice & Palliative Medicine. She is also on the Board of Directors of athenahealth, Inc.
Angus Grant, PhD
Business Development and Global Alliances
Angus Grant joined Celgene as Vice President North American Regulatory Affairs in September 2006, first to manage and grow the regulatory staff and function in the Summit NJ Headquarters, and then in Europe. After 3 years as Head of Europe RA, Angus has returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, where he has since closed multiple innovative deals and collaborations and built the Alliance Management function, now managing over 30 collaborations ranging from pharma, biotech, academic and patient advocacy.
Prior to joining Celgene, Dr. Grant was the Executive Director for Alliance Management for Novartis Oncology, Senior Director, Regulatory Affairs, Oncology Strategy with Merck KGaA/EMD Pharmaceuticals, and previously help positions in Regulatory Affairs at both Aventis Pharmaceuticals and SmithKline Beecham Pharmaceuticals. Prior to working in industry, Dr. Grant served as a Senior Staff Fellow at the U.S. Food and Drug Administration Center for Biologics, Office of Therapeutics, and conducted his post-doctoral research in immunotherapy with the National Cancer Institute. Dr. Grant received his Ph.D. in Anatomy/Immunology from the Medical College of Virginia.
Paul Howard, PhD
Director, Center for Medical Progress
Manhattan Institute for Policy Research
Paul Howard, Ph.D., is a Manhattan Institute senior fellow and director of the Manhattan Institute’s Center for Medical Progress. He is also a contributor to The Apothecary, the influential Forbes blog on health care policy and entitlement reform, and a regular columnist for The Morning Consult.
He has written on a wide variety of medical policy issues, including FDA reform, biopharmaceutical innovation, consumer-driven health care, Medicare and Medicaid policy, and health care reform. He is often quoted on health care issues and his columns and essays have appeared in national publications, including Bloomberg View, The Wall Street Journal, National Affairs, USA Today, Real Clear Politics, New York Post, Investor’s Business Daily, Health Affairs, and FoxNews.com.
He is also a member of the Manhattan Institute’s Project FDA, a committee of physician-scientists, economists, medical ethicists, and policy experts. Their purpose is to show how twenty-first-century technologies can help better inform FDA regulations and accelerate the drug-development and drug-approval process while maintaining drug safety.
In 2012, Howard served on the Health Care Policy Advisory Group for the presidential campaign of former Massachusetts governor Mitt Romney. He has also testified twice before Congress. In 2013 and 2014, he served on an expert panel as a judge for Celgene’s Innovation Impact Awards.
Howard joined the Manhattan Institute in 2000, working as deputy director of the Center for Legal Policy where he edited research papers, managed legal policy analyses, and organized conferences.
Howard received his Ph.D. in political science from Fordham University in 2003, and is a graduate of the College of the Holy Cross in Worcester, Massachusetts.
Bray Patrick-Lake, MFS
Director of Patient Engagement, Duke Clinical and Translational Science Award (CTSA)
and Director of Stakeholder Engagement, Clinical Trials Transformation Initiative (CTTI)
Ms. Patrick-Lake supports efforts to actively engage participant partners in Duke research programs, as well as patient advocacy organizations and other stakeholders in CTTI efforts to improve clinical trials. She implements strategies to enhance awareness of CTTI’s work, particularly with patient advocates, and extend its impact by working in partnership with the patient advocacy community on research design and conduct, and improvement of the clinical trial enterprise. Ms. Patrick-Lake also serves as the co-chair for the Advisory Committee to the NIH Director on the Precision Medicine Initiative.
In 2010, Ms. Patrick-Lake founded the PFO Research Foundation in response to the lack of definitive scientific information regarding the condition of patent foramen ovale (PFO) after being a patient in an aborted clinical trial. Ms. Patrick-Lake has served as a patient representative at the FDA on a variety of advisory committees and panels, in workgroups for EMA and NIH, as a guest lecturer and an external reviewer for IOM, and as a patient stakeholder or co-investigator for AHRQ and PCORI grants. She is a member of the PCORnet Coordinating Center’s Executive Leadership Committee where she develops patient engagement strategies, MDEpiNet’s National Medical Device Registry Task Force, MDIC’s Patient-centered Benefit-Risk Steering Committee, ACC Foundation’s Patient-centered Care (PC3) Shared Decision Making Workgroup, DIA’s Patient Fellowship Selection Committee, TVT Registry Stakeholder Advisory Committee, and is a board member for the Alliance for Headache Disorders Advocacy.
Nancy Roach founded Fight Colorectal Cancer (Fight CRC) in 2005, nine years after her mother in law was diagnosed with colorectal cancer. Recognizing the need for an advocacy organization, she established Fight CRC to provide focus, infrastructure and support for colorectal cancer survivors, caregivers, and those touched by the disease. Since then, Nancy has played a vital role championing the need for a cure for colon and rectal cancer, through screening, awareness and research. Her efforts as an advocate have supported education and support for patients as well as the research community. Her leadership and passion has fostered a community of advocates supporting state and federal policies that has led to increased colorectal cancer research opportunities across the country. Over the last four years, Fight Colorectal Cancer has directed over $250,000 dollars in research funding to young investigators. She currently serves as the Chair of the Board of Directors.
Ms. Roach serves on the National Cancer Institute (NCI) Clinical Trial and Translational Research Advisory Committee. She is on the Executive Committee on the Clinical Trials Transformation Initiative, an FDA-Duke public-private partnership, and is a past chair of its finance committee. She has been involved with cooperative groups and SPORES, and currently serves on the NCI Colon Task force. She serves on the Department of Defense Congressionally Directed Medical Research Program Integration Panel, which funds colorectal cancer research. She is a past chair of the NCI Patient Advocate Steering Committee, and received the NCI Director’s Service Award when she stepped down. She has also received the Preventing Colorectal Cancer Champion Award and the Colon Cancer Alliance Sapphire Visionary Award in recognition of her efforts on behalf of patients. She has spoken on behalf of patients at meetings such as the American Association for Cancer Research, the Friends of Cancer Research / Brookings Institute Conference on Clinical Research and the Oxford University-Duke University-McMaster University Sensible Guidelines for Clinical Trials.
Sue Sheridan is the Director of Patient Engagement for the Patient-Centered Outcomes Research Institute (PCORI). She leads the Patient Engagement team, which develops and implements tools, programs, and processes to encourage meaningful engagement of patients and other stakeholders in all PCORI’s activities.
Before joining PCORI, Sheridan was the external lead of the Patients for Patient Safety program at the World Health Organization (WHO), where she helped develop and implement a global network of patients who built national and regional strategic plans for patient engagement for various WHO initiatives. Sheridan had previously spent 10 years in patient advocacy inspired by adverse family experiences in the healthcare system.
Sheridan co-founded and is past president of Parents of Infants and Children with Kernicterus (brain damage from jaundice), who engaged with the healthcare system to implement a new standard of care in jaundice management. She is also a co-founder of Consumers Advancing Patient Safety, which helps organizations engage patients as partners in developing patient-safety solutions. Prior to her leadership in patient engagement, she worked as a finance banker for international trade.
Sheridan received her BA from Albion College, her MIM and MBA from the Thunderbird School of Global Management, and her DHL (Doctor of Humane Letters) from Adrian College.